Altimmune, Inc. - 8-K Filing

Altimmune announces positive topline results for pemvidutide's Phase 2 RECLAIM trial in alcohol use disorder (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits(d) ExhibitsNo)

SEC EDGAR · July 28, 2026, 11:05 UTC

Tickers: $ALT

Read the full article at SEC EDGAR

More Regulatory news

Solana Co - 10-Q Filing SEC EDGAR · November 12, 2026, 13:42 UTC
Solana Co - 8-K Filing SEC EDGAR · November 12, 2026, 13:41 UTC
DeFi Development Corp. - 8-K Filing SEC EDGAR · November 12, 2026, 13:41 UTC
Stablecoin Development Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:40 UTC
BCP Investment Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:36 UTC
OneWater Marine Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:37 UTC
Moleculin Biotech, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:37 UTC
Investcorp Credit Management BDC, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:37 UTC
Presurance Holdings, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:35 UTC
Corteva, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:34 UTC